They were ARID1A (tazemetostat, PLX2853), NF1 (trametinib, cobimetinib) and PTEN (GSK2636771, AZD8186) in three IMT patients, and KRAS (trametinib, cobimetinib, binimetinib) in one MT patient (Table S9). The gene discussed is ARID1A; the disease is inflammatory myofibroblastic tumor.